Improving Development of Drug Treatments for Pregnant Women and the Fetus.

David, Anna L; Ahmadzia, Homa; Ashcroft, Richard; Bucci-Rechtweg, Christina; Spencer, Rebecca N; Thornton, Steve

David, Anna L; Ahmadzia, Homa; Ashcroft, Richard; Bucci-Rechtweg, Christina; Spencer, Rebecca N; Thornton, Steve.

Afiliação

David AL; Elizabeth Garrett Anderson Institute for Women's Health, University College London, 74 Huntley Street, London, UK. a.david@ucl.ac.uk.
Ahmadzia H; NIHR UCLH Biomedical Research Centre, 149 Tottenham Court Road, London, UK. a.david@ucl.ac.uk.
Ashcroft R; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The George Washington University, Washington, DC, USA.
Bucci-Rechtweg C; City University, London, UK.
Spencer RN; Head, Pediatric and Maternal Health Policy, Global Drug Development Regulatory Affairs, Pediatric Center of Excellence, Novartis Pharmaceuticals Corporation, Basel, Switzerland.
Thornton S; Elizabeth Garrett Anderson Institute for Women's Health, University College London, 74 Huntley Street, London, UK.

Ther Innov Regul Sci ; 56(6): 976-990, 2022 11.

Article em En | MEDLINE | ID: mdl-35881237

Assuntos

Cardiotônicos; Gestantes; Criança; Feminino; Feto; Humanos; Recém-Nascido; Placenta; Gravidez; RNA Mensageiro

Palavras-chave

Adverse event; Fetus; Pregnancy clinical trial; Safety; Therapeutics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiotônicos / Gestantes Tipo de estudo: Prognostic_studies Limite: Child / Female / Humans / Newborn / Pregnancy Idioma: En Revista: Ther Innov Regul Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google